Site Search

Share

X

Search Results

Comments to HHS Supporting Regulatory Safe Harbor For Ancillary Costs

ACS CAN was joined by 22 other organizations in proposing the HHS Office of Inspector General (OIG) adopt a new regulatory safe harbor from the ...

ACS CAN Proposal For Regulatory Safe Harbor for Financial Support of Patients on Trials

In response to an annual request from the Department of Health and Human Services (HHS), ACS CAN has proposed a safe harbor from the Anti-Kickback Statute that would allow trial sponsors to provide financial support to trial participants to offset non-medical costs.  ACS CAN Proposal For Regulatory Safe Harbor for Financial Support of Patients on Trials ...

ACS CAN Supports the Clinical Trial Modernization Act (H.R. 8412)

Clinical trials are key to advancing new standards of care that can improve survival and quality of life for people with cancer. However, cost to trial participants is often a barrier to their enrollment. ...

ACS CAN Comments on March-In Rights Framework

In response to a request from the National Institute of Starndards and Technology (NIST), ACS CAN has offered comments on the use of march-in rights to address drug costs.  ACS CAN Comments on March-In Rights Framework ...

Understanding Provider Utilization of Cancer Biomarker Testing

Biomarker testing is an important step to accessing precision medicine, including targeted therapies that can lead to improved survivorship and better quality of life for cancer patients. However, not all communities are benefitting from the latest advancements in biomarker testing and precision medicine. ... that prevent patients from benefiting from biomarker testing and precision medicine, and working to ensure all patients benefit, regardless of race, ethnicity, gender, age, sexual orientation, socioeconomic status, or zip code.   ACS CAN conducted a survey of 315 oncology providers ...

Community Letter in Support of the DIVERSE Trials Act (H.R. 5030/S. 2706)

ACS CAN and more than 150 organizations representing patients, providers and health equity advocates sent a letter to Congress urging them to pass the ... allow sponsors to provide patients with technology necessary to facilitate remote participation in clinical trials; and require the Department of Health and Human Services (HHS) to create guidance on the use of decentralized trials to increase trial diversity. Community Letter in Support of the DIVERSE Trials Act (H.R. 5030/S. 2706) ...

Barriers to Patient Enrollment in Therapeutic Clinical Trials for Cancer

Download Executive Summary of Landscape Report Download Landscape Report on Barriers to Patient Enrollment in Cancer Clinical Trials Download Recommendations for Overcoming ... to Patient Enrollment in Cancer Clinical Trials Download Figures and Tables The objective of cancer research is to generate new knowledge that can be used to improve survival and quality of life for patients with cancer. Clinical trials are the key step in advancing potential new cancer ... documents and processes to ensure education and comprehension by patients of the research in which they are contemplating participation. Provide cost transparency by providing full coverage analyses on all trials to clearly articulate responsibility for all anticipated trial costs. Trial ...

Improving Access to Biomarker Testing

The knowledge and practice of precision medicine in cancer have been progressing rapidly and advances have led to targeted cancer therapies that can improve patient survival and quality life. Treatment with targeted therapy often requires diagnostic testing to analyze biological samples ... clinical use does not always follow, and testing rates lag behind clinical guideline recommendations. As highlighted in a recent ACS CAN survey of cancer patients and survivors, only one-third of respondents reported having biomarker testing. Of those who reported not receiving biomarker ...

Type

Priority Issue

State

Policy Issue

Judicial Advocacy